Incyte News

Oppenheimer Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $82

Moomoo NewsDec 13 16:31 ET · Ratings

Weekly Buzz: Tech stocks hit high scores on ominous day

Kevin TraversDec 13 16:29 ET

Market Mixed on Friday the 13th | Livestock

Kevin TraversDec 13 10:46 ET

Incyte (NASDAQ:INCY) Shareholders Have Lost 22% Over 5 Years, Earnings Decline Likely the Culprit

Simply Wall StDec 13 09:24 ET

BMO Capital Maintains Incyte(INCY.US) With Sell Rating, Maintains Target Price $52

Moomoo NewsDec 13 07:31 ET · Ratings

TD Cowen Maintains Incyte(INCY.US) With Buy Rating, Maintains Target Price $86

Moomoo NewsDec 13 07:31 ET · Ratings

TD Cowen Reaffirms Their Buy Rating on Incyte (INCY)

TipRanksDec 13 07:26 ET · Ratings

Incyte's Growth Prospects Hampered by Pipeline Setbacks and Market Challenges

TipRanksDec 13 07:06 ET

Thursday Ends in Index Declines | Wall Street Today

Kevin TraversDec 12 16:29 ET

Market Falls Thursday, Producer Inflation Grows, and Tech Pulls Back From Records | LiveStock

Kevin TraversDec 12 11:21 ET

Positive Outlook on Incyte's Stock: InMIND Study Validates Tafasitamab Combination Efficacy and Safety

TipRanksDec 12 02:07 ET

Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock

Kevin TraversDec 11 10:47 ET

Market Falls Wednesday, but Googles Chip Impresses | WST

Kevin TraversDec 10 16:19 ET

Incite Says Phase 3 Trial of Monjuvi in Follicular Lymphoma Patients Meets Endpoints

MT NewswiresDec 10 11:27 ET

Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock

Kevin TraversDec 10 10:51 ET

Incyte Says Phase 3 InMIND Trial Met Primary Endpoint of PFS

TipRanksDec 10 10:40 ET

Express News | Incyte's Late-Breaking ASH 2024 Data Show Tafasitamab (Monjuvi) Significantly Improves Progression-Free Survival In Relapsed/Refractory Follicular Lymphoma, Meeting Phase 3 InMIND Trial Endpoints; U.S. SBLA Filing Planned By Year-End 2024

BenzingaDec 10 10:30 ET

Stifel Maintains Incyte(INCY.US) With Hold Rating, Maintains Target Price $75

Moomoo NewsDec 10 08:31 ET · Ratings

Stifel Nicolaus Sticks to Their Hold Rating for Incyte (INCY)

TipRanksDec 10 07:46 ET · Ratings

Incyte's BET Inhibitor Program Holds Promise Amid Safety Concerns and Strategic Uncertainty

TipRanksDec 10 06:55 ET